Alice Capogrosso Sansone1, Irma Convertino1, Maria Teresa Galiulo1, Stefano Salvadori2, Stefania Pieroni2, Tamara Knezevic2, Stefania Mantarro1, Alessandra Marino1, Manfred Hauben3,4, Corrado Blandizzi1,5, Marco Tuccori6. 1. Division of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, 56126, Pisa, Italy. 2. Institute of Clinical Physiology, National Research Council, Via Moruzzi, 56124, Pisa, Italy. 3. Pfizer Inc., 235 East 42nd Street, Mail Stop 150-3-80 W, New York, NY, 10017, USA. 4. Department of Medicine, New York University School of Medicine, New York, NY, USA. 5. Unit of Adverse Drug Reactions Monitoring, Tuscan Regional Centre of Pharmacovigilance, University Hospital of Pisa, Via Roma 55, 56126, Pisa, Italy. 6. Unit of Adverse Drug Reactions Monitoring, Tuscan Regional Centre of Pharmacovigilance, University Hospital of Pisa, Via Roma 55, 56126, Pisa, Italy. m.tuccori@ao-pisa.toscana.it.
Abstract
INTRODUCTION: Proton pump inhibitors (PPIs) have been implicated in the occurrence of moderate to severe myopathies in several case reports. AIM: This study was performed to assess the reporting risk of muscular adverse drug reactions (ADRs) associated with PPIs in the Italian National Network of Pharmacovigilance database. METHODS: A disproportionality analysis (case/non-case) was performed using spontaneous reports collected in the database between July 1983 and May 2016. Reporting odds ratio (ROR) and 95% confidence intervals (CIs) were calculated as a measure of disproportionality. In a secondary and tertiary analysis, we explored the association of PPIs with muscular ADRs after taking into account the masking effect of statins. Moreover, the possibility of an interaction between PPIs and statins, leading to the occurrence of muscular ADRs, was also tested. RESULTS: The study was carried out on 274,108 reports. The ROR of muscular ADRs for PPIs, adjusted for age and gender, was 1.484 (95% CI 1.204-1.829; p < 0.001), whereas the ROR for rhabdomyolysis was 0.621 (95% CI 0.258-1.499). Similar results were obtained in the secondary analysis. The tertiary analysis, where PPIs were considered regardless of whether their role was suspected or concomitant, showed a potential disproportionate reporting for the combination PPIs-rhabdomyolysis (ROR 1.667, 95% CI 1.173-2.369; p < 0.01). The PPIs-statins combination was not associated with an enhanced ROR of muscular ADRs/rhabdomyolysis compared with statins alone. CONCLUSIONS: This explorative study suggests that the class of PPIs could be involved in reports of muscular ADRs, rather than any other ADR, more frequently than any non-statin drug. Our results must be corroborated by further studies.
INTRODUCTION: Proton pump inhibitors (PPIs) have been implicated in the occurrence of moderate to severe myopathies in several case reports. AIM: This study was performed to assess the reporting risk of muscular adverse drug reactions (ADRs) associated with PPIs in the Italian National Network of Pharmacovigilance database. METHODS: A disproportionality analysis (case/non-case) was performed using spontaneous reports collected in the database between July 1983 and May 2016. Reporting odds ratio (ROR) and 95% confidence intervals (CIs) were calculated as a measure of disproportionality. In a secondary and tertiary analysis, we explored the association of PPIs with muscular ADRs after taking into account the masking effect of statins. Moreover, the possibility of an interaction between PPIs and statins, leading to the occurrence of muscular ADRs, was also tested. RESULTS: The study was carried out on 274,108 reports. The ROR of muscular ADRs for PPIs, adjusted for age and gender, was 1.484 (95% CI 1.204-1.829; p < 0.001), whereas the ROR for rhabdomyolysis was 0.621 (95% CI 0.258-1.499). Similar results were obtained in the secondary analysis. The tertiary analysis, where PPIs were considered regardless of whether their role was suspected or concomitant, showed a potential disproportionate reporting for the combination PPIs-rhabdomyolysis (ROR 1.667, 95% CI 1.173-2.369; p < 0.01). The PPIs-statins combination was not associated with an enhanced ROR of muscular ADRs/rhabdomyolysis compared with statins alone. CONCLUSIONS: This explorative study suggests that the class of PPIs could be involved in reports of muscular ADRs, rather than any other ADR, more frequently than any non-statin drug. Our results must be corroborated by further studies.
Authors: Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant Journal: J Am Coll Cardiol Date: 2002-08-07 Impact factor: 24.094
Authors: A Bate; M Lindquist; I R Edwards; S Olsson; R Orre; A Lansner; R M De Freitas Journal: Eur J Clin Pharmacol Date: 1998-06 Impact factor: 2.953
Authors: Rafael Alis; Fabian Sanchis-Gomar; Jennifer Risso-Ballester; Carme Perez-Quilis; Jose Cortell-Ballester; Marco Romagnoli; Jose R Blesa; Enzo Emanuele Journal: Atherosclerosis Date: 2014-12-31 Impact factor: 5.162
Authors: A Di Grande; V Giustolisi; V Tabita; C Giuffrida; S Riccobene; C Le Moli; V Cannone; E Maira; G Narbone; F Nigro; R Paradiso; C Tramontana Journal: Clin Ter Date: 2008 May-Jun